ASBPHealthcare · BiotechnologyASBP Stock Forecast: Aspire Biopharma Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile.
ASBP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Aspire Biopharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Aspire Biopharma Holdings, Inc. — and when they’d sell — is the membership.
ASBP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ASBP, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ASBP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Aspire Biopharma Holdings, Inc. (ASBP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 244.4×
- Price / book
- 0.3×
- EV / EBITDA
- −0.3×
Cheaper than 75% of US stocks
Cheaper than 3% of US stocks
Cheaper than 88% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- 565.4%
- Earnings growth (YoY)
- —
- Gross margin
- 20.3%
- Operating margin
- −5758.7%
- Net margin
- −1.9%
Higher than 98% of US stocks
Higher than 23% of US stocks
Higher than 3% of US stocks
Higher than 28% of US stocks
- Return on equity
- 383.9%
- Return on assets
- −74.7%
- Dividend yield
- —
Higher than 99% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ASBP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASBP appears on the weeks it earns a place.
Frequently asked questions about ASBP stock
How does Ticker Nerd's model rank ASBP?
As at 1 Aug 2026, Aspire Biopharma Holdings, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
What is the ASBP stock forecast for 2030?
No analyst covering Aspire Biopharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASBP are extrapolating price history, which says nothing about the business.
What does Aspire Biopharma Holdings, Inc. do?
Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company focused on developing and marketing disruptive sublingual delivery technology for drugs and supplements.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company focused on developing and marketing disruptive sublingual delivery technology for drugs and supplements. This patent-pending platform enables rapid absorption directly into the bloodstream through tissues under the tongue, bypassing the gastrointestinal tract to enhance bioavailability, speed of onset, and reduce side effects like gastrointestinal irritation. The company's lead product, Instaprin, is a soluble, pH-neutral, fast-acting sublingual aspirin powder designed for cardiology emergencies and pain management. Aspire Biopharma Holdings Inc. applies its technology across a pipeline of reformulated pharmaceuticals, including melatonin sleep aids, vitamins D, E, and K, testosterone, semaglutide, anti-nausea, anti-psychotic, erectile dysfunction, seizure medications, and others. In the consumer space, it commercializes BUZZ BOMB, a sublingual caffeine supplement in flavors like Tropical Fruit and Mixed Berry, offered through its subsidiary Buzz Bomb Caffeine Company LC for quick energy and cognitive support. Founded in 2021 and headquartered in Estero, Florida, Aspire Biopharma Holdings Inc. operates in the biotechnology sector, targeting improved drug delivery for emergency and everyday health applications.
CEO Mr. Kraig T. Higginson · United States · https://aspirebiolabs.com